

TRENDSⁱⁿ Pharmacological Sciences

INCLUDING TOXICOLOGICAL SCIENCES

February 2004

Vol. 25, No. 2

pp. 59–112

Editor Katharine Barnes

Assistant Editor Gillian MacKenzie

Editorial Coordinator Patricia Ward

Illustrations The Studio

Publishing Manager O. Claire Moulton

Editorial Enquiries

Trends in Pharmacological Sciences
Elsevier,
84 Theobald's Road,
London, UK WC1X 8RR
tel: +44 20 7611 4400
fax: +44 20 7611 4470
e-mail: tips@elsevier.com

Subscription Enquiries

E-mail: trends.subs@qss.co.uk

Advisory Editorial Board

S.G. Amara, *Pittsburgh, PA, USA*
H. Betz, *Frankfurt, Germany*
N.J.M. Birdsall, *London, UK*
N.G. Bowery, *Birmingham, UK*
J.N. Crawley, *Bethesda, MD, USA*
A.C. Cuello, *Montréal, Canada*
A. Dray, *Montréal, Canada*
J.R. Fozard, *Basel, Switzerland*
B.B. Fredholm, *Stockholm, Sweden*
T.P. Kenakin, *Research Triangle Park, NC, USA*
R.W. Kerwin, *London, UK*
B.K. Kobilka, *Stanford, CA, USA*
M. Lazdunski, *Valbonne, France*
G-Q. Liu, *Nanjing, China*
C.A. Maggi, *Florence, Italy*
J. Meldolesi, *Milan, Italy*
M. Mishina, *Tokyo, Japan*
W.H. Moolenaar, *Amsterdam, The Netherlands*
C.P. Page, *London, UK*
R. Ruffolo, Jr, *King of Prussia, PA, USA*
T.K. Sawyer, *Cambridge, MA, USA*
R.J. Summers, *Melbourne, Australia*
T. Tanaka, *Tsu, Japan*
D. Wallach, *Rehovot, Israel*
Z.G. Wang, *Beijing, China*
S.P. Watson, *Birmingham, UK*

Update

Research Focus

- 59** Possible involvement of the endocannabinoid system in the actions of three clinically used drugs
Christopher J. Fowler
- 61** The structure of the GRK2–G $\beta\gamma$ complex: intimate association of G-protein signaling modules
Tohru Kozasa

Opinion

- 67** β_2 -Adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis
Jacques De Keyser, Esther Zeinstra, Jop Mostert and Nadine Wilczak
- 72** Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
Valery V. Novokhatny, Gary J. Jesmok, Kyle A. Landskroner, Victor J. Marder and Thomas P. Zimmerman

Review

- 76** From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function
Stephen A. Douglas, Dashyant Dhanak and Douglas G. Johns
- 86** Novel strategies for the pharmacological management of type 2 diabetes
Arash Nourparvar, Angela Bulotta, Umberto Di Mario and Riccardo Perfetti
- 92** β -Secretase inhibition for the treatment of Alzheimer's disease – promise and challenge
Martin Citron
- 98** Epilepsy, CNS viral injury and dynorphin
Marylou V. Solbrig and George F. Koob
- 105** The molecular acrobatics of arrestin activation
Vsevolod V. Gurevich and Eugenia V. Gurevich

Forthcoming articles

Parkinson's disease, pesticides and individual vulnerability
M. Paolini, A. Sapone and F.J. Gonzalez

Is ethanol a pro-drug? Role of acetaldehyde in the central effects of ethanol
E. Quertemont and S. Tambour

The heterogeneous course of drug transit through the body
A. Dokoumetzidis, V. Karalis, A. Iliadis and P. Macheras

Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)
J.M. O'Donnell and H-T. Zhang

Do pediatric drugs cause developing neurons to commit suicide?
J.W. Olney, C. Young, V. Jevtovic-Todorovic and C. Ikonomidou

Immunomodulatory and neuroprotective effects of inosine
G. Haskó, M.V. Sitkovsky and C. Szabó

Available online at www.sciencedirect.com



TRENDS
www.trends.com

Cover: In this issue, Douglas and colleagues review recent developments in the pharmacology of urotensin-II, first characterized in the marine goby fish, and discuss its role in the mammalian cardiorenal system. Antagonists of urotensin-II are currently under development as novel therapeutic agents for the clinical management of hypertension, heart failure, renal failure and diabetes in humans. The cover image was kindly provided by Kevin Kelley and Kim Anthony. Cover design by Kate Jones.